The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. AIMS. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. METHODS. We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20). We compared the baseline characteristics, changes of laboratory data and body weight. RESULTS. At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups. AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group. The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, P < 0.01). On the other hands, the body weight significantly increased in pioglitazone group and did not change in sitagliptin group. Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12-73.1, P = 0.04). CONCLUSIONS. Administration of liraglutide improved T2DM but also improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective study, liraglutide and pioglitazone, but not sitagliptin, decreased liver fibrosis index APRI (calculated as the aspartate aminotransferase (AST) to platelet count ratio), and the improvement was associated with weight loss and a marked reduction in AST and ALT levels [149].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · BMJ · doi:10.1136/bmj.39335.541782.ad · Cited by 10,766 · cited 1×
“This study was conducted according to STROBE statement [23].”
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406 · cited 2×
“The evaluation of liver fibrosis depended on calculation of aspartate aminotransferase (AST) to platelet counts ratio (APRI) index [22].”
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · cited 1×
“Improvement of insulin resistance and sensitivity has therapeutic effect in preventing the progression of NAFLD because the accumulation of triglycerides in hepatocytes is considered to be the first step in the current two-hit theory of the pathophysiological development of NAFLD [5].”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 12×
“Serum DPP-4 activity is reported to be significantly higher in NAFLD patients [17].”
InfluentialPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“The disorder is thought to be common because the incidence of its typical features, fatty liver disease, obesity, and type 2 DM, is increasing [25].”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Since in a randomized controlled trial intended for NAFLD patients, pioglitazone demonstrated alteration of liver inflammation but did not affect on improvement of liver fibrosis [6].”
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 2×
“Weight reduction via lifestyle intervention is generally recommended as an initial step in the management of NAFLD [27], and its effectiveness was proven in a randomized controlled trial [8].”
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 2×
“NAFLD is a liver disease that is characterized histologically by hepatic steatosis, lobular inflammation, and hepatocellular ballooning [24], and it was reported that at least 3% of the patients progressed to cirrhosis [3].”
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 2×
“Particularly, trials of glucose lowering agents such as metformin and pioglitazone have yielded promising results [18, 26].”
Research works printed but not linked: 2
- 10.1111/j.1572-0241.2003.07486.x · doi:10.1111/j.1572-0241.2003.07486.x · Paper page
- 10.1053/jhep.2003.50420 · doi:10.1053/jhep.2003.50420 · Paper page
Cited by
Items 101–147 of 147
Shinozaki, S., Tahara, T., Miura, K., Lefor, A. K., & Yamamoto, H. (2023) · Life · doi:10.3390/life13061327 · Cited by 6
“reported the effectiveness of liraglutide for the treatment of patients with NAFLD, and the liraglutide group showed significant weight and ALT reduction [39].”
BackgroundLiu, Y., Wu, H., Wang, Z., Wu, J., Ying, S., Huang, M., & Li, Y. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.07.013 · Cited by 6
Gilijamse, P. W., Demirkıran, A., van Wagensveld, B. A., Ackermans, M. T., Romijn, J. A., Nieuwdorp, M., ter Horst, K. W., & Serlie, M. J. M. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.04.022 · Cited by 5
Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways
Yaribeygi, H., Kashian, K., Moghaddam, K. I., Karim, S. R., Bagheri, N., Karav, S., Jamialahmadi, T., Rizzo, M., & Sahebkar, A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108928 · Cited by 4
Supaglutide alleviates hepatic steatosis in monkeys with spontaneous MASH
Wang, Q., Zhou, Y., Ni, Y., Wang, Z., Lou, Y.-R., Yang, Z., Gong, L., Liang, Y., Zeng, W., & Prud’homme, G. J. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01513-7 · Cited by 4
Ito, H., Someya, R., Ando, S., Araki, R., Tsugami, E., Matsumoto, S., Inoue, H., Antoku, S., Yamasaki, T., Mori, T., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14002 · Cited by 4
“8 Ohki et al. 9 retrospectively investigated the effects of liraglutide (0.3 mg/ day for the first week, 0.6 mg/day for the next week, and finally up to the limit dose of 0.9 mg/day if necessary), sitagliptin (50 mg/day up to 100 mg/day if necessary), and pioglitazone (15 mg/day) in patients with type 2 diabetes and n…”
BackgroundInfluentialFilipova, E. P., Uzunova, K. H., & Vekov, T. Y. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0059-7 · Cited by 4
“, 2012 [77] SIT ↓ aspartate aminotransferase (P = 0.”
Simão, M. C. S. A., Caires, C. A., de Almeida, C. J. B., Costa, I. M., Alves, I. N., Neves, I. D. O. R., Fulgêncio, I. M., Moreira, L. M. V., Amaral, M. D. F. L., & Guimarães, V. C. (2020) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e3881.2020 · Cited by 4
Zhang, F., Tang, L., Li, J., Yan, Z., Li, J., & Tong, N. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s293307 · Cited by 4
“gain than sitagliptin users, they also experienced greater improvements in NAFLD.(29) Abdominal obesity, and especially VAT, is closely related to the incidence of IR, T2D, and CVDs.”
BackgroundTreatment options for managing atherogenic dyslipidemia and fatty liver disease
Rizzo, M., Montalto, G., & Al‐Rasadi, K. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.902051 · Cited by 4
“For example, in 82 Japanese NAFLD patients with type-2 diabetes, the administration of liraglutide improved glycemic control and also had beneficial effects on liver inflammation, liver fibrosis and body weight [25].”
BackgroundOikawa, R., Nakanishi, Y., Fujimoto, K., Wakasa, A., Iwadare, M., Iwao, H. K., Ishida, R., & Iwai, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-81663-w · Cited by 3
Incretin as a Novel Treatment Strategy for NAFLD/NASH
Takeda, Y., Ikeda, R., & Kondo, T. (2016) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00264-2 · Cited by 3
Fernandes, L. G. D. M., Osório De Castro, S., Santos, S. S., Gomes Ferreira, S., Andrade, L., & Henriques, C. (2024) · Medicina Interna · doi:10.24950/rspmi.2522 · Cited by 3
What is Non‐Alcoholic Fatty Liver Disease (NAFLD), and Why is it Important?
Farrell, G. C., McCullough, A. J., & Day, C. P. (2013) · Wiley eBooks · doi:10.1002/9781118556153.ch1 · Cited by 3
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Barkondaj, B., Nargis, T., Chakrabarti, P., Mukhopadhyay, S., Biswas, K., Ganguly, D., Chaterjee, C., Sengupta, N., & Hazra, A. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_139_22 · Cited by 2
Crabtree, T. S. J., Rowles, S. V., Tarpey, S., Kennedy, A., Chalmers, J., Nayar, R., Lee, A. J., Darzy, K. H., Winocour, P. H., Lindsay, J., et al. (2019) · British Journal of Diabetes · doi:10.15277/bjd.2019.227 · Cited by 2
“Median ALT at baseline, U/L (IQR) Female - Normal ALT 16 (13-18) Female - Raised ALT 31 (25-43) Male - Normal ALT 23 (18-26) Male - Raised ALT 45 (38-57)”
BackgroundAghajanpoor, M., Gholampourdehaki, M., Mosaed, R., Mirzaii‐Dizgah, I., & Vosughi, A. (2024) · Annals of Military and Health Sciences Research · doi:10.5812/amh-144009 · Cited by 2
Pharmacologic Management of Non-Alcoholic Fatty Liver Disease
Goh, G. B. (2014) · Advances in Pharmacoepidemiology & Drug Safety · doi:10.4172/2167-1052.1000157 · Cited by 2
“A separate study found that liraglutide improved BMI, aminotransferases and APRI (AST to platelet ratio index) score, a surrogate non-invasive marker of hepatic fibrosis [81] Two other studies investigated the use of sitagliptin, demonstrating beneficial effects ranging from reduction in BMI, aminotransferases, balloo…”
BackgroundPharmacological Approaches for Nonalcoholic Fatty Liver Disease
Ionică, F. E., Negreș, S., Bejenaru, L. E., Bejenaru, C., & Chiriţă, C. (2016) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2016-0037 · Cited by 2
Fontana, J., Kučera, O., Anděl, M., & Červinková, Z. (2019) · General Physiology and Biophysics · doi:10.4149/gpb_2019016 · Cited by 2
“…findings of incretin-based therapies on liver parameters of patients with diabetes in clinical practice (Tushuizen et al. 2006; Buse et al. 2007; Klonoff et al. 2008; Kenny et al. 2010; D’Amico 2011; Sathyanarayana et al. 2011; Cuthbertson et al. 2012; Ohki et al. 2012; Vilsbøll et al. 2012).”
BackgroundClinical Response to Xultophy Possibly Varies from Each Different Metabolic Function
Bando, H., Kazuki, S., Tomoya, O., Naoki, K., Hatakeyama, S., Kobayashi, T., & Noboru, I. (2021) · Edelweiss Applied Science and Technology · doi:10.33805/2576-8484.190 · Cited by 2
Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
Williams, K. L., Augustine, M., Sujakhu, E., Magadia, J., Crawford, L., Knott, A., Hamilton, S., & Obiaka, U. (2024) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2024.101775 · Cited by 1
Chen, J. I., Delibasi, B. T., Wang, J., Tran, T., Hu, C., & Randall, C. W. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04626-7 · Cited by 1
“Further, GLP-1 agonists have been associated with improved surrogate fibrosis indices like FIB-4, AST-to-platelet count ratio index (APRI), non-alcoholic fatty liver disease fibrosis score (NFS), and liver stiffness [15– 17].”
Sakai, T. I. K. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000598 · Cited by 1
Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease
Mihai, C., Mihai, B. M., & Prelipcean, C. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_14 · Cited by 1
Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
Glatthar, R., & Arch, R. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc274 · Cited by 1
A New Stereo Method Based On The Detector Of Local Structures
Cyganek, B., & Borgosz, J. (2002) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.37744
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Tashima-Horie, K., Ogino, J., Yoneda, C., Nishino, T., & Hashimoto, N. (2019) · Tokyo Women's Medical University Journal · doi:10.24488/twmuj.2018008
de Oliveira, G. C. M., Baptista, G. M., Lima, E. I., Bittencourt, A. M. V., & Andrade, L. J. D. O. (2019) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v18i2.25909
Simonovic, D., Deljanin-Ilić, M., Kocic, G. M., Lazarević, G., Đorđević, B., Šarić, S., Stojanović, S., & Ilić, S. (2018) · AFMN Biomedicine · doi:10.5937/afmnai1904294s
Fan, S., Shi, X., Fan, Y., Yang, L.-L., Yao, J., & Feng, P. (2020) · Medicine · doi:10.1097/md.0000000000020695
On Meal Effects and DPP-4 Inhibition Islet- and Incretin Hormones in Health and Type 2 Diabetes
Alsalim, W. (2020) · Lund University Publications (Lund University)
Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review
Imbeth‐Acosta, P. L., Pájaro-Galvis, N., Leal-Martínez, V., Rico-Fontalvo, J. E., Daza-Arnedo, R., Castañeda-López, O., Cardona-Blanco, M., Mercado-Anillo, K., Lucas-Daza, J., Pérez-Calvo, C., et al. (2020) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2020.1010013
The pathophysiology of gut–liver connection
Maroni, L., Fianchi, F., Miele, L., & Svegliati‐Baroni, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821927-0.00002-4
Albaugh, V. L. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.05.032
van de Wier, B. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20160705bw
The pleiotropic effects of liraglutide in obesity-linked diseases
Kozdrowicki, M., Kaleta, K., Kajtel, A., Tekieli, B., Kęska, M., Lorkowska-Zawicka, B., & Bujak-Giżycka, B. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.2.2
Bzoma, M., Bochenek, H., Kamiński, P., Czerepak, I., Gugulska, J., Bielicka, A., Szwarc, T., Kałwik, M., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3493
Huang, S., Xi, Y., Hong, Y., & Hu, C. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2720-5290
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021) · Figshare · doi:10.6084/m9.figshare.17273245
Tesoro, N. A., Rivera, F. B., Bantayan, N. R. B., Magalong, J. V., Tomada, R., Wong, M. A., Tangco, G. A., Pine, P. L. S., Manha, J. K., Tanni, E. S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101623
“Meanwhile, despite our heterogenous results against OHAs, several studies have shown that incretin therapies produce greater and more consistent reductions in aminotransferases and liver fat than DPP-4 inhibitors and SGLT2 inhibitors [43 – 45].”
Barkondaj, B., Chakrabarti, P., Mukhopadhyay, S., Ganguly, D., Sengupta, N., Chatterjee, C., Hazra, A., & Bose, C. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_397_25
Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease
Karshina, O. O., Sabirov, I. S., & Mohammad, E. A. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-240-8-110-118
Limwongse, S., Chatpattanasiri, P., Phuphuang, P., Tungthaweethong, K., Sutheerayongprasert, K., Aunprom-Me, W., Kositamongkol, C., & Phisalprapa, P. (2026) · World Journal of Hepatology · doi:10.4254/wjh.123353
Metadata
- Authors
- Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K.
- Affiliations
- Mitsui Memorial Hospital (JP)
- The University of Tokyo (JP)
- Yamanashi Prefectural Hospital Organization (JP)
- Corresponding author
- Yoshida, Haruhiko
- Venue
- The Scientific World Journal
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 1537-744X (ISSN-L)
- PMC
- PMC3425807
- OpenAlex
- W2113064802
- Cited by
- 139
- References
- 29
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 14 · 2023: 11 · 2022: 10 · 2021: 15 · 2020: 15 · 2019: 11 · 2018: 11 · 2017: 6 · 2016: 14 · 2015: 10 · 2014: 9 · 2013: 3
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The Scientific World JOURNAL (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, non-alcoholic fatty liver disease, type 2 diabetes, sitagliptin, pioglitazone, weight loss, liver inflammation, ALT, HbA1c, glycemic control, GLP-1 receptor agonists
- MeSH terms
- Sitagliptin Phosphate, Liraglutide, Pioglitazone, Adult, Alanine Transaminase, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Evaluation, Drug Therapy, Combination, Fatty Liver, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Inflammation, Liver Cirrhosis, Male, Middle Aged, Platelet Count, Pyrazines, Retrospective Studies, Triazoles, Comorbidity, Multivariate Analysis, Logistic Models, Odds Ratio, Treatment Outcome, Thiazolidinediones, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.